Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating LMN-101 at Several Dose Levels in Healthy Volunteers Challenged With Campylobacter Jejuni

Next Previous
Trial Profile

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating LMN-101 at Several Dose Levels in Healthy Volunteers Challenged With Campylobacter Jejuni

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 12 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs LMN 101 (Primary)
  • Indications Campylobacter infections; Traveller's diarrhoea
  • Focus Therapeutic Use
  • Sponsors Lumen Bioscience

Most Recent Events

  • 12 Jan 2023 New trial record
  • 04 Jan 2023 According to Lumen Bioscience media release, the company announced several funding milestones supporting the development of its therapeutics to prevent serious diarrheal diseases. The first is a $5 million grant from the Bill Melinda Gates Foundation for this second Phase 2 study of LMN-101, The trial design is similar to the first Phase 2 trial of LMN-101 (NCT04182490) but with enhancements to shed light on the unexpectedly low placebo attack rate that made that earlier trial uninterpretab

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top